Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

1997 • 2,510 citations

Histone deacetylases and cancer: causes and therapies

2001 • 1,833 citations

Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen

2001 • 1,684 citations

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1998 • 1,091 citations

Histone deacetylase inhibitor selectively induces p21 ^WAF1 expression and gene-associated histone acetylation

2000 • 1,091 citations

Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia

1998 • 1,021 citations

The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases

2000 • 946 citations

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

1998 • 899 citations

Regulation of activity of the transcription factor GATA-1 by acetylation

1998 • 686 citations

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1999 • 686 citations

The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

1996 • 662 citations

Histone deacetylases, transcriptional control, and cancer

2000 • 622 citations

Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL

1998 • 571 citations

p21 ^WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells

1998 • 530 citations

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

2002 • 505 citations

FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.

1994 • 484 citations

FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor

1998 • 481 citations

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

2001 • 451 citations

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

1996 • 421 citations

Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects

1999 • 394 citations

Histone acetylation and disease

2001 • 331 citations

Transcriptional Regulation of the MDR1 Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y

1998 • 289 citations

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

1994 • 253 citations

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

1999 • 235 citations

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression

1998 • 229 citations

Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines

1994 • 193 citations

Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase

2002 • 189 citations

Effects of trichostatins on differentiation of murine erythroleukemia cells.

1987 • 171 citations

Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na⁺/I⁻Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells

2001 • 150 citations

Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 Cells

1994 • 143 citations

Chronic Oral Administration of CI-994: A Phase I Study

2001 • 136 citations

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

2000 • 108 citations

Epigenetic Regulation of Gelsolin Expression in Human Breast Cancer Cells

1999 • 107 citations

Mechanism of Cell Cycle Arrest Caused by Histone Deacetylase Inhibitors in Human Carcinoma Cells.

2000 • 107 citations